The content is available as a PDF (6.6 MB).
References
- 1.Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol. Rev. 1992;130:41–68. doi: 10.1111/j.1600-065X.1992.tb01520.x. [DOI] [PubMed] [Google Scholar]
- 2.Evans RW. Immunosuppressive therapy as a determinant of transplantation outcomes. Transplantation. 1993;55:1297–1305. doi: 10.1097/00007890-199306000-00017. [DOI] [PubMed] [Google Scholar]
- 3.Tcheng JE. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757–1764. doi: 10.1161/01.CIR.90.4.1757. [DOI] [PubMed] [Google Scholar]
- 4.Neal CE, Meis LC. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer. Semin. nucl. Med. 1994;24:272–285. doi: 10.1016/S0001-2998(05)80019-4. [DOI] [PubMed] [Google Scholar]
- 5.Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu. Rev. Immun. 1994;12:433–455. doi: 10.1146/annurev.iy.12.040194.002245. [DOI] [PubMed] [Google Scholar]
- 6.Pietersz GA, Krauer K. Antibody-targeted drugs for the therapy of cancer. J. Drug Targeting. 1994;2:183–215. doi: 10.3109/10611869408996804. [DOI] [PubMed] [Google Scholar]
- 7.Holliger P, Prospero T, Winter G. “Diabodies”: Small bivalent and bispecific antibody fragments. Proc. natn. Acad. Sci. U.S.A. 1993;90:6444–6448. doi: 10.1073/pnas.90.14.6444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Janda KD, Lo CH, Li T, Barbas CF, Wirsching P, Lerner RA. Direct selection for a catalytic mechanism from combinatcjrial antibody libraries. Proc. natn. Acad. Sci. U.S.A. 1994;91:2532–2536. doi: 10.1073/pnas.91.7.2532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Burton DR, Barbas CF. Human antibodies from combinatorial libraries. Adv. Immun. 1994;57:191–280. doi: 10.1016/S0065-2776(08)60674-4. [DOI] [PubMed] [Google Scholar]
- 10.Lonberg N. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 1994;368:856–859. doi: 10.1038/368856a0. [DOI] [PubMed] [Google Scholar]
- 11.Green LL. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genet. 1994;7:13–21. doi: 10.1038/ng0594-13. [DOI] [PubMed] [Google Scholar]
- 12.Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu. Rev. Biochem. 1988;57:321–347. doi: 10.1146/annurev.bi.57.070188.001541. [DOI] [PubMed] [Google Scholar]
- 13.Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immun. Res. 1993;12:244–257. doi: 10.1007/BF02918256. [DOI] [PubMed] [Google Scholar]
- 14.Morgan BP. Clinical complementology: recent progress and future trends. Eur. J. clin. Invest. 1994;24:219–228. doi: 10.1111/j.1365-2362.1994.tb01078.x. [DOI] [PubMed] [Google Scholar]
- 15.Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. Beta amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immun. 1994;152:5050–5059. [PubMed] [Google Scholar]
- 16.Wang, Y., Rollins, S.A., Madri, J.A. & Matis, L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. natn. Acad. Sci. U.S.A. (in the press). [DOI] [PMC free article] [PubMed]
- 17.Rinder, C.S. et al. A monoclonal antibody directed at the human C5 component of complement serves as a potent inhibitor of leukocyte and platelet activation during simulated extracorporeal circulation. J. clin. Invest. (in the press).
- 18.Evans, M.J. et al. In vivo and in vitro inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Molec. Immun. (in the press). [DOI] [PubMed]